Skip to main content

ADvanced Validation of A Novel TB Active disease diagnostic to address Global unmet needs: a European consortium approach

Objective

Tuberculosis (TB) remains an EU and global healthcare priority resulting in over 1.4 million deaths each year. Despite this and efforts to reduce TB by the EU commission, the WHO and others, a simple, rapid, diagnostic test for active tuberculosis (TB) remains elusive. Current diagnostic procedures, while accounting for over $1 bn globally, are poorly selective for active TB, hold risks for healthcare personnel, are slow to yield results and costly.


The large potential and high unmet need provide a clear target for commercialisation of a point-of-care (POC) test. Using over 400 clinical samples, ProteinLogic (a UK based diagnostics company) have demonstrated proof of concept for a ground-breaking approach using a panel of protein biomarkers on human serum samples that profile the cell mediated patient response to TB.

The objectives of the eight structured work packages within this three year project are to build on the validation of the biomarker TB panel transitioning from a laboratory assay to Biosensia’s novel microfluidic POC platform that has already been successfully proven with a variety of human analytes. Reagents will be developed as part of this project to ensure reduced costs and security of commercial supply. A unique instrument reader plus TB cartridge-based product will be developed to meet EU regulatory standards. The products will be validated in order to confirm analytical and clinical performance, and to provide evidence of major time, cost & performance improvements compared to current TB testing practises.
Successful commercialisation will lead to the creation of over 30 new jobs and will stimulate further private investment in each of the companies.

In summary, ADVANTAGE has the potential to deliver a disruptive POC TB diagnostic test that can help eradicate the massive TB burden not only in EU but also globally.

Field of science

  • /social sciences/sociology/social issues/social inequality
  • /engineering and technology/medical engineering/medical laboratory technology/laboratory samples analysis
  • /medical and health sciences/clinical medicine/pneumology/tuberculosis
  • /engineering and technology/medical engineering/medical laboratory technology/diagnostic technologies
  • /social sciences/economics and business/business and management/commerce

Call for proposal

H2020-SMEINST-2-2014
See other projects for this call

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

PROTEINLOGIC LIMITED
Address
Shakespeare House 42 Newmarket Road
CB5 8EP Cambridge Cambridgeshire
United Kingdom
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 3 031 548,69

Participants (1)

BIOSENSIA LIMITED

Participation ended

Ireland
EU contribution
€ 551 847,31
Address
Unit 1 16 Nova Ucd University College Dublin Belfield
4 Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)